Chronic Obstructive Pulmonary Disease, COPD
Conditions
Keywords
chronic obstructive pulmonary disease, COPD, Chronic bronchitis
Brief summary
The symptoms associated with COPD include overproduction of mucus and inflammation in the lungs. Overproduction of mucus results in impaired lung function and it encourages bacterial growth and associated COPD exacerbations. Therefore, a treatment that inhibits mucus overproduction or blocks inflammation could benefit COPD patients. The drug under evaluation in this study, BIO-11006 Inhalation Solution, is a new drug that may inhibit overproduction of mucus and may have important anti-inflammatory properties.
Detailed description
COPD encompasses a number of chronic lung disorders that obstruct the airways and may be accompanied by airway hyperactivity. The most common form of COPD is a combination of chronic bronchitis and emphysema. Many of the signs and symptoms associated with chronic bronchitis are a result of airway mucus hypersecretion induced by chronic inflammation of the airways. Clinically, mucus hypersecretion results in impaired gas exchange and compromised mucociliary clearance, encouraging bacterial colonization and associated exacerbations. A treatment that inhibits mucus hypersecretion or blocks inflammation could benefit COPD patients with chronic bronchitis. The drug under evaluation in this study, BIO 11006, is a new therapeutic agent that may inhibit mucus secretion and may have important anti inflammatory properties. In this study, BIO-11006 will be administered to COPD patients with chronic bronchitis, and the effects lung function will be assessed.
Interventions
DRUGBIO-11006 Inhalation Solution
75 mg of BIO-11006 administered once per day for 21 days by nebulizer
DRUGPlacebo
Placebo given once daily for 21 days by nebulizer
DRUGBIO-11006
125 mg BIO-11006 given twice per day for 21 days by nebulizer
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
BioMarck Pharmaceuticals, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinically stable male or female outpatients, 45 years of age or older * Active COPD with chronic bronchitis indicated by: (1) FEV1 = 40% to 70%, (2) FEV1/FVC ≤70%, (3)Chronic productive cough for 3 months in each of 2 successive years, and (4) Sputum (phlegm) production at least several days a week over the past 4 weeks * Current or previous smoker with a 20-pack year history
Exclusion criteria
* Treatment with oral prednisone during the 6 weeks before enrollment * Changed inhaled corticosteroid dose or long acting bronchodilator dose during the 6 weeks before enrollment * Treatment with oxygen (with the exception of night time oxygen) during the 6 weeks before enrollment * Current asthma as determined by the investigator * Change in smoking status during the previous 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of BIO-11006 when administered once or twice daily for 21 days to subjects with COPD by assessing adverse events, physical exams, vital signs, pulmonary function, 12 lead electrocardiogram, clinical blood chemistries, hematology, and urinalysis. | Throughout study |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of BIO-11006 when administered once or twice daily for 21 days to subjects with COPD by assessing the change from baseline in pulmonary function. | Day 21 of the study |
Countries
United States
Outcome results
None listed